Genomma Lab Internacional SAB de CV Announces Earnings Results for the Third Quarter Ended September 30, 2016
November 09, 2016 at 09:29 am EST
Share
Genomma Lab Internacional SAB de CV announced earnings results for the third quarter ended September 30, 2016. For the quarter, the company reported net profits of MXN 512.2 million (USD 25.7 million), increase of 171% compared with third-quarter 2015. Net sales reached MXN 2.88 billion, increasing by 11.6% in the quarter compared with the equivalent period in 2015. Earnings before interest, taxes, depreciation, and amortisation (EBITDA) increased by 55.2% to MXN 601.3 million.
Genomma Lab Internacional SAB de CV is a Mexico-based over-the-counter pharmaceutical (OTC pharmaceutical), generic drugs (GD) and personal care products company. The Company is engaged in the development, distribution and marketing of a range of products within different brands, for such treatments as anti-acne, varicose vein, hair loss, sexual stimulation and influenza; as well as analgesics and antifungals. The Companyâs product portfolio includes such brands as Asepxia, Cicatricure, Goicoechea, Bengue, Diabet TX, Genoprazol, Goicotabs, Shot B, SilkaMedic, Siluet 40, Nikzon, X Ray, Next, Touch Me, Lomecan V and QG5, among others. The Company is a parent of a number of controlled entities, which have operations established in Mexico, the United States, Peru, Chile, Ecuador and Honduras, among others. In June 2014, the Company acquired 50% stake in Grupo Comercial e Industrial Marzam SA de CV.
GENOMMA LAB INTERNACIONAL, S.A.B. DE C.V. 
